Clinical Trial Update: A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Onartuzumab (MetMAb) in combination with Bevacizumab plus platinum and paclitaxel or with pemetrexed plus platinum for non-squamous non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Onartuzumab (onartuzumab)
• PACLITAXEL (PACLITAXEL)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED